COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 5 FDA records to the applicant name Pulmonx Corporation. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 1 entry is a PMA supplement. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jun 29, 2018 to Sep 11, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NJK appears in 4 of the 5 linked filings. The collection spans 2 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P180002, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 700 Chesapeake Dr., Redwood City, CA, 94063. Recorded on P180002/S032, decision dated Sep 11, 2026.
Device categories in this collection
Valve, Pulmonary; Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector).
Changes described in PMA records
The FDA recorded an approval decision dated 2026-09-11 for P180002/S032, a real-time process supplement from Pulmonx Corporation covering the Zephyr Endobronchial Valve System, product code NJK under anesthesiology. The listed statement describes changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve, filed under change design/components/specifications/material. The supplement number establishes a link to the original P180002 approval; it does not approve the whole system anew.
The record gives no detail on the prior or revised funnel design, materials, or specifications, and no evidence of bench performance, safety, or clinical effectiveness beyond the stated purpose. The decision is a manufacturing process notice, not a new indication or trial result.
It is not established what specific change was made to the funnel component, what testing supported it, or whether any labeling changed.
FDA approval-order wording
Approval for changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve.
Sep 11, 2026 · Real-Time ProcessFDA’s recorded scope: approval for the qualification of Confluent Medical (Fremont, CA) as a second source supplier for the nitinol retainer component of the Zephyr 5.5-LP EBV
Jun 17, 2026 · 30-Day NoticeFDA’s recorded scope: Removal of the ambient aeration step of the ethylene oxide (EO) sterilization process.
Mar 17, 2026 · 30-Day NoticeFDA’s recorded scope: Approval of the Pulmonx Zephyr Endobronchial Valve System. The device is an implantable bronchial valve indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.
Jun 29, 2018Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.